- Home
- NUS vs PRTA Comparison
NUS vs PRTA Comparison
Compare NUS & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUS
- PRTA
- Stock Information
- Founded
- NUS 1984
- PRTA 2012
- Country
- NUS United States
- PRTA Ireland
- Employees
- NUS N/A
- PRTA N/A
- Industry
- NUS Other Pharmaceuticals
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- NUS Health Care
- PRTA Health Care
- Exchange
- NUS Nasdaq
- PRTA Nasdaq
- Market Cap
- NUS 572.2M
- PRTA 472.1M
- IPO Year
- NUS 1996
- PRTA N/A
- Fundamental
- Price
- NUS $12.15
- PRTA $8.20
- Analyst Decision
- NUS Hold
- PRTA Buy
- Analyst Count
- NUS 2
- PRTA 10
- Target Price
- NUS $6.88
- PRTA $14.86
- AVG Volume (30 Days)
- NUS 676.6K
- PRTA 1.2M
- Earning Date
- NUS 08-07-2025
- PRTA 08-04-2025
- Dividend Yield
- NUS 1.97%
- PRTA N/A
- EPS Growth
- NUS N/A
- PRTA N/A
- EPS
- NUS 2.03
- PRTA N/A
- Revenue
- NUS $1,626,325,000.00
- PRTA $10,341,000.00
- Revenue This Year
- NUS N/A
- PRTA N/A
- Revenue Next Year
- NUS $0.98
- PRTA $389.77
- P/E Ratio
- NUS $6.00
- PRTA N/A
- Revenue Growth
- NUS N/A
- PRTA N/A
- 52 Week Low
- NUS $5.32
- PRTA $4.32
- 52 Week High
- NUS $12.41
- PRTA $22.83
- Technical
- Relative Strength Index (RSI)
- NUS 66.78
- PRTA 58.73
- Support Level
- NUS $11.83
- PRTA $8.05
- Resistance Level
- NUS $12.41
- PRTA $8.73
- Average True Range (ATR)
- NUS 0.43
- PRTA 0.38
- MACD
- NUS 0.02
- PRTA -0.05
- Stochastic Oscillator
- NUS 70.64
- PRTA 47.62
About NUS Nu Skin Enterprises Inc.
Nu Skin Enterprises Inc is a health and beauty direct-selling company. It has two primary product categories: beauty products and wellness products. The company develops and distributes nutritional, weight-management products, and food supplements under the Nu Skin and Pharmanex brands, respectively. The company has operations internationally, in more than 50 countries across the Americas, Europe, and the Asia-Pacific.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.